Viracta Therapeutics (NASDAQ:VIRX) Rating Reiterated by HC Wainwright

Viracta Therapeutics (NASDAQ:VIRX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $4.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 324.40% from the company’s previous close.

Viracta Therapeutics Stock Up 31.9 %

Shares of VIRX opened at $0.94 on Tuesday. The firm has a 50-day moving average price of $0.90 and a 200 day moving average price of $0.70. The firm has a market capitalization of $37.01 million, a PE ratio of -0.71 and a beta of 0.93. Viracta Therapeutics has a 52-week low of $0.43 and a 52-week high of $2.38.

Viracta Therapeutics (NASDAQ:VIRX) last announced its earnings results on Thursday, March 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.05). On average, equities analysts expect that Viracta Therapeutics will post -1.28 EPS for the current year.

Hedge Funds Weigh In On Viracta Therapeutics

Large investors have recently made changes to their positions in the business. Two Sigma Investments LP bought a new position in shares of Viracta Therapeutics during the 4th quarter valued at about $87,000. Renaissance Technologies LLC boosted its position in shares of Viracta Therapeutics by 45.8% during the 4th quarter. Renaissance Technologies LLC now owns 139,787 shares of the company’s stock valued at $204,000 after purchasing an additional 43,888 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Viracta Therapeutics by 3.0% during the 4th quarter. Geode Capital Management LLC now owns 224,438 shares of the company’s stock valued at $327,000 after purchasing an additional 6,502 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Viracta Therapeutics by 22.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 179,621 shares of the company’s stock valued at $263,000 after purchasing an additional 33,290 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Viracta Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,114,368 shares of the company’s stock valued at $4,759,000 after purchasing an additional 207,108 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.